文献速递临床试验与 GCP基础与转化研究

营养干预调节白塞综合征患者肠道菌群:MAMBA随机对照试验方案

Modulation of gut microbiota through nutritional interventions in Behçet's syndrome patients (the MAMBA study): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-06-09

本研究为随机、开放、交叉设计试验,纳入90例白塞综合征患者,随机分配至乳蛋素食饮食、地中海饮食或补充丁酸盐的地中海饮食三种等热量饮食各3个月。主要结局为白塞综合征胃肠道及全身症状相对基线的变化,次要结局包括肠道菌群组成、短链脂肪酸产生及炎症和抗氧化谱的变化。

要点

  • 三种等热量饮食分别为乳蛋素食、地中海饮食及补充1.8g/天口服丁酸盐的地中海饮食。
  • 主要结局为白塞综合征胃肠道和全身症状相对基线的变化。
  • 次要结局包括肠道菌群组成、短链脂肪酸产生及炎症和抗氧化谱变化。

核心结论

  • 该研究旨在探究饮食干预能否改善白塞综合征患者的临床表现并调节其肠道菌群。

研究设计与样本

  • 随机、开放、交叉试验,纳入90例白塞综合征患者,随机分配至三种饮食各3个月。
  • 三种饮食为乳蛋素食饮食、地中海饮食或补充丁酸盐的地中海饮食,均为等热量。

关键数值与推荐

  • 乳蛋素食饮食不含肉、禽、鱼,包含富含菊粉和抗性淀粉的食物、蛋、乳制品及植物性食物。
  • 地中海饮食包含所有食物类别,每周提供两份鱼和三份新鲜及加工肉类。
  • 补充丁酸盐的地中海饮食与地中海饮食相似,但每日补充1.8g口服丁酸盐。
  • 主要结局为白塞综合征胃肠道和全身症状相对基线的变化。
  • 次要结局为肠道菌群组成、短链脂肪酸产生及炎症和抗氧化谱相对基线的变化。

临床怎么用

  • 该方案尚待结果验证,目前不能据此推荐特定饮食用于白塞综合征的临床管理。

局限性

  • 研究为开放设计,未设盲。
  • 原文未报告样本量计算依据及统计功效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Behçet's syndrome (BS) is a systemic inflammatory disorder of unknown etiology, and it is characterized by a wide range of potential clinical manifestations. Recent evidence suggests that the gut microbiota (GM) in BS has low biodiversity with a significant depletion in butyrate producers. The aim of the present project is to investigate whether a dietary intervention could ameliorate the clinical manifestations and modulate the GM of individuals with BS. METHODS: This is a randomized, open, cross-over study that involves 90 individuals with BS, who will be randomly assigned to one of three different diets for 3 months: a lacto-ovo-vegetarian diet (VD), a Mediterranean diet (MD), or a Mediterranean diet supplemented with butyrate (MD-Bt). The VD will contain inulin-resistant and resistant-starch-rich foods, eggs, and dairy in addition to plant-based food, but it will not contain meat, poultry, or fish. The MD will contain all food categories and will provide two portions per week of fish and three portions per week of fresh and processed meat. The MD-Bt will be similar to the MD but supplemented with 1.8 g/day of oral butyrate. The three different diets will be isocaloric and related to the participants' nutritional requirements. Anthropometric measurements, body composition, blood, and fecal samples will be obtained from each participant at the beginning and the end of each intervention phase. The primary outcomes will be represented by the change from baseline of the BS gastrointestinal and systemic symptoms. Changes from baseline in GM composition, short-chain fatty acid (SCFA) production, and the inflammatory and antioxidant profile will be considered as secondary outcomes. DISCUSSION: BS is a rare disease, and, actually, not all the available treatments are target therapies. A supportive treatment based on dietary and lifestyle issues, able to restore immune system homeostasis, could have a high impact on cost sustainability for the treatment of such a chronic and disabling inflammatory condition. TRIAL REGISTRATION: clinicaltrials.gov: NCT03962335. Registered on 21 May 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Pagliai G, Dinu M, Fiorillo C, et al. Modulation of gut microbiota through nutritional interventions in Behçet's syndrome patients (the MAMBA study): study protocol for a randomized controlled trial. Trials. 2020. PMID: 32517729. doi:10.1186/s13063-020-04444-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。